BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenthal EM, Hall EW, Rosenberg ES, Harris A, Nelson NP, Schillie S. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations. Vaccine 2020;38:8206-15. [PMID: 33160756 DOI: 10.1016/j.vaccine.2020.10.067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Carrico J, La EM, Talbird SE, Chen Y, Nyaku MK, Carias C, Mellott CE, Marshall GS, Roberts CS. Value of the Immunization Program for Children in the 2017 US Birth Cohort. Pediatrics 2022;150. [DOI: 10.1542/peds.2021-056007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 LaMori J, Feng X, Pericone CD, Mesa-Frias M, Sogbetun O, Kulczycki A. Hepatitis vaccination adherence and completion rates and factors associated with low compliance: A claims-based analysis of U.S. adults. PLoS One 2022;17:e0264062. [PMID: 35176102 DOI: 10.1371/journal.pone.0264062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Huang S, Kao J. Management of Hepatitis B in Persons Who Inject Drugs (PWID). Curr Hepatology Rep 2021;20:158-165. [DOI: 10.1007/s11901-021-00574-w] [Reference Citation Analysis]
4 Pappas SC. Hepatitis B and Health Care Workers. Clin Liver Dis 2021;25:859-74. [PMID: 34593158 DOI: 10.1016/j.cld.2021.06.010] [Reference Citation Analysis]
5 Janssen RS, Bruxvoort K, Jacobsen SJ, Slezak J, David C, Hyer R, Poland GA. Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination. Vaccine 2021;39:5666-72. [PMID: 34404556 DOI: 10.1016/j.vaccine.2021.07.100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hirst A, Hyer RN, Janssen RS. Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations. Vaccine 2021;39:4733-41. [PMID: 34030898 DOI: 10.1016/j.vaccine.2021.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Lee GH, Lim SG. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update. Expert Rev Vaccines 2021;20:487-95. [PMID: 33783302 DOI: 10.1080/14760584.2021.1908133] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
8 Ward JW. Hepatitis B Vaccines. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Heplisav-B cost effective versus Engerix-B. PharmacoEcon Outcomes News 2020;867:16-16. [DOI: 10.1007/s40274-020-7313-4] [Reference Citation Analysis]